Sean Fenske, Editor-in-Chief03.12.24
Orthopediatrics has launched a solution to address early onset scoliosis (EOS), the company’s 71st pediatric orthopedic product.
The system represents the firm’s first product to address the condition. It is specifically intended for those associated with or at risk of Thoracic Insufficiency Syndrome.
Greg Odle, president of the OrthoPediatrics’ Scoliosis Division, expressed his excitement for the launch of this new system. “We are excited to enter the Early Onset Scoliosis treatment market with the RESPONSE Rib & Pelvic System. While this is our first treatment option in the EOS market, we continue to work with pediatric orthopedic surgeons to develop additional treatment options for EOS patients.”
The RESPONSE product family addition includes implants and instruments for rib and pelvic fixation, as well as devices to facilitate the connection of the fixation points.
The new product is compatible with the 5.5/6.0 and 4.5/5.0 RESPONSE systems.
The system represents the firm’s first product to address the condition. It is specifically intended for those associated with or at risk of Thoracic Insufficiency Syndrome.
Greg Odle, president of the OrthoPediatrics’ Scoliosis Division, expressed his excitement for the launch of this new system. “We are excited to enter the Early Onset Scoliosis treatment market with the RESPONSE Rib & Pelvic System. While this is our first treatment option in the EOS market, we continue to work with pediatric orthopedic surgeons to develop additional treatment options for EOS patients.”
The RESPONSE product family addition includes implants and instruments for rib and pelvic fixation, as well as devices to facilitate the connection of the fixation points.
The new product is compatible with the 5.5/6.0 and 4.5/5.0 RESPONSE systems.